These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 38772290)

  • 1. Discovery of novel coumarin-based KRAS-G12C inhibitors from virtual screening and Rational structural optimization.
    Shi JT; Hou SJ; Cheng L; Zhang HJ; Mu HX; Wang QS; Wang ZY; Chen SW
    Bioorg Chem; 2024 Jul; 148():107467. PubMed ID: 38772290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis and pharmacological evaluation of bicyclic and tetracyclic pyridopyrimidinone analogues as new KRAS
    Xiao X; Lai M; Song Z; Geng M; Ding J; Xie H; Zhang A
    Eur J Med Chem; 2021 Mar; 213():113082. PubMed ID: 33309163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of KRas G12C-IN-3 and Pomalidomide-based PROTACs as degraders of endogenous KRAS G12C with potent anticancer activity.
    Li L; Wu Y; Yang Z; Xu C; Zhao H; Liu J; Chen J; Chen J
    Bioorg Chem; 2021 Dec; 117():105447. PubMed ID: 34715575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective apoptosis-inducing activity of synthetic hydrocarbon-stapled SOS1 helix with d-amino acids in H358 cancer cells expressing KRAS
    Xu LL; Li CC; An LY; Dai Z; Chen XY; You QD; Hu C; Di B
    Eur J Med Chem; 2020 Jan; 185():111844. PubMed ID: 31706640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of novel quinazoline-based covalent inhibitors of KRAS G12C with various cysteine-targeting warheads as potential anticancer agents.
    Li L; Zhao H; Liao H; Chen J; Liu J; Chen J
    Bioorg Chem; 2021 May; 110():104825. PubMed ID: 33774492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of novel Quinazoline-based KRAS G12C inhibitors as potential anticancer agents.
    Li L; Zhao H; Peng X; Liu J; Mai R; Chen J; Lin L; Chen T; Yan J; Shi J; Chen J
    Bioorg Med Chem; 2022 Oct; 71():116962. PubMed ID: 35987104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis, and evaluation of 4(1H)-quinolinone and urea derivatives as KRAS
    Cheng R; Lv X; Bu H; Xu Q; Wu J; Xie K; Tang J; Wang L; Zhuang J; Zhang Y; Zhang Y; Yan C; Lai Y
    Eur J Med Chem; 2022 Dec; 244():114808. PubMed ID: 36228411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of ARS-1620 analogs as KRas G12C inhibitors with high in vivo antitumor activity.
    Zhao H; Li L; Liu J; Mai R; Chen J; Chen J
    Bioorg Chem; 2022 Apr; 121():105652. PubMed ID: 35158284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The discovery of novel imidazo[1,2-
    Song Q; Zhang Q; Fan X; Kayaat F; Lv R; Li J; Wang Y
    Org Biomol Chem; 2024 Jul; 22(26):5374-5384. PubMed ID: 38869445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition.
    Misale S; Fatherree JP; Cortez E; Li C; Bilton S; Timonina D; Myers DT; Lee D; Gomez-Caraballo M; Greenberg M; Nangia V; Greninger P; Egan RK; McClanaghan J; Stein GT; Murchie E; Zarrinkar PP; Janes MR; Li LS; Liu Y; Hata AN; Benes CH
    Clin Cancer Res; 2019 Jan; 25(2):796-807. PubMed ID: 30327306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery, optimization and biological activity evaluation of genipin derivatives as potential KRAS G12D inhibitors.
    Sun R; Hu Y; Liu X; Lin Y; Lv D; Li W; Fu L; Jiang F
    Bioorg Chem; 2024 Jul; 148():107460. PubMed ID: 38781668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor.
    Janes MR; Zhang J; Li LS; Hansen R; Peters U; Guo X; Chen Y; Babbar A; Firdaus SJ; Darjania L; Feng J; Chen JH; Li S; Li S; Long YO; Thach C; Liu Y; Zarieh A; Ely T; Kucharski JM; Kessler LV; Wu T; Yu K; Wang Y; Yao Y; Deng X; Zarrinkar PP; Brehmer D; Dhanak D; Lorenzi MV; Hu-Lowe D; Patricelli MP; Ren P; Liu Y
    Cell; 2018 Jan; 172(3):578-589.e17. PubMed ID: 29373830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploring Targeted Degradation Strategy for Oncogenic KRAS
    Zeng M; Xiong Y; Safaee N; Nowak RP; Donovan KA; Yuan CJ; Nabet B; Gero TW; Feru F; Li L; Gondi S; Ombelets LJ; Quan C; Jänne PA; Kostic M; Scott DA; Westover KD; Fischer ES; Gray NS
    Cell Chem Biol; 2020 Jan; 27(1):19-31.e6. PubMed ID: 31883964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. D-1553: A novel KRAS
    Shi Z; Weng J; Niu H; Yang H; Liu R; Weng Y; Zhu Q; Zhang Y; Tao L; Wang Z; Huh SJ; Jiang Y; Mei H; Dai X; Zhang L; Wang Y
    Cancer Sci; 2023 Jul; 114(7):2951-2960. PubMed ID: 37158138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diverse alterations associated with resistance to KRAS(G12C) inhibition.
    Zhao Y; Murciano-Goroff YR; Xue JY; Ang A; Lucas J; Mai TT; Da Cruz Paula AF; Saiki AY; Mohn D; Achanta P; Sisk AE; Arora KS; Roy RS; Kim D; Li C; Lim LP; Li M; Bahr A; Loomis BR; de Stanchina E; Reis-Filho JS; Weigelt B; Berger M; Riely G; Arbour KC; Lipford JR; Li BT; Lito P
    Nature; 2021 Nov; 599(7886):679-683. PubMed ID: 34759319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. KRAS Inhibitor Resistance in
    Suzuki S; Yonesaka K; Teramura T; Takehara T; Kato R; Sakai H; Haratani K; Tanizaki J; Kawakami H; Hayashi H; Sakai K; Nishio K; Nakagawa K
    Clin Cancer Res; 2021 Oct; 27(20):5697-5707. PubMed ID: 34365406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of the Clinical Development Candidate
    Fell JB; Fischer JP; Baer BR; Blake JF; Bouhana K; Briere DM; Brown KD; Burgess LE; Burns AC; Burkard MR; Chiang H; Chicarelli MJ; Cook AW; Gaudino JJ; Hallin J; Hanson L; Hartley DP; Hicken EJ; Hingorani GP; Hinklin RJ; Mejia MJ; Olson P; Otten JN; Rhodes SP; Rodriguez ME; Savechenkov P; Smith DJ; Sudhakar N; Sullivan FX; Tang TP; Vigers GP; Wollenberg L; Christensen JG; Marx MA
    J Med Chem; 2020 Jul; 63(13):6679-6693. PubMed ID: 32250617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Computationally Empowered Workflow Identifies Novel Covalent Allosteric Binders for KRAS
    Mortier J; Friberg A; Badock V; Moosmayer D; Schroeder J; Steigemann P; Siegel F; Gradl S; Bauser M; Hillig RC; Briem H; Eis K; Bader B; Nguyen D; Christ CD
    ChemMedChem; 2020 May; 15(10):827-832. PubMed ID: 32237114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ganoderma microsporum immunomodulatory protein combined with KRAS
    Hua WJ; Hwang WL; Yeh H; Lin ZH; Hsu WH; Lin TY
    Int J Biol Macromol; 2024 Feb; 259(Pt 2):129291. PubMed ID: 38211909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concomitant KRAS mutations attenuate sensitivity of non-small cell lung cancer cells to KRAS G12C inhibition.
    Vaclova T; Chakraborty A; Sherwood J; Ross S; Carroll D; Barrett JC; Downward J; de Bruin EC
    Sci Rep; 2022 Feb; 12(1):2699. PubMed ID: 35177674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.